[1] PIERCE WM, WAITE LC.Bone-targeted carbonic anhydrase inhibitors: effect of a proinhibitor on bone resorption in vitro.Proc Soc Exp Biol Med.1987;186(1):96-102.
[2] GU W, WU C, CHEN J, et al. Nanotechnology in the targeted drug delivery for bone diseases and bone regeneration. Nanomedicine. 2013;8:2305-2317.
[3] CHEN J, DING J, ZHANG Y, et al.Polyion complex micelles with gradient pH-sensitivity for adjustable intracellular drug delivery.Polym Chem. 2015;6(3):397-405.
[4] NEGUSSIE AH, MILLER JL, REDDY G, et al.Synthesisand and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome. J Control Release.2010;143(2):265-273.
[5] CHEN B, YANG JZ, WANG LF, et al.Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.BMC Cancer. 2015;15:752.
[6] ABRAHAMSE H, KRUGER CA, KADANYO S, et al.Nanoparticles for Advanced Photodynamic Therapy of Cancer.Photomed Laser Surg. 2017;35(11):581-588.
[7] DANG J, HE H, CHEN D, et al.Manipulating tumor hypoxia toward enhanced photodynamic therapy (PDT).Biomater Sci.2017;5(8): 1500-1511.
[8] MAEDA H.Polymer therapeutics and the EPR effect.J Drug Target. 2017;25(9-10):781-785.
[9] WANG Y, LIU Z, LI T, et al.Enhanced Therapeutic Effect of RGD-Modified Polymeric Micelles Loaded With Low-Dose Methotrexate and Nimesulide on Rheumatoid Arthritis. Theranostics. 2019;9(3):708-720.
[10] HUANG L, WANG X, CAO H, et al.A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice.Biomaterials.2018;182:58-71.
[11] YAMASHITA S, KATSUMI H, HIBINO N, et al.Development of PEGylated aspartic acid-modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis. Biomaterials. 2018;154:74-85.
[12] XIE Y, LIU C, HUANG H, et al.Bone-targeted delivery of simvastatin- loaded PEG-PLGA micelles conjugated with tetracycline for osteoporosis treatment.Drug Deliv Transl Res.2018;8(5):1090-1102.
[13] KE X, LIN W, LI X, et al.Synergistic dual-modified liposome improves targeting and therapeutic efficacy of bone metastasis from breast cancer.Drug Deliv.2017;24(1):1680-1689.
[14] HAGHIRALSADAT F, AMOABEDINY G, NADERINEZHAD S, et al. EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.Pharm Res. 2017;34(12):2891-2900.
[15] LIU J, ZENG Y, SHI S, et al.Design of polyaspartic acid peptide-poly (ethylene glycol)-poly (epsilon-caprolactone) nanoparticles as a carrier of hydrophobic drugs targeting cancer metastasized to bone.Int J Nanomedicine.2017;12:3561-3575.
[16] RAICHUR V, VEMULA KD, BHADRI N, et al.Zolendronic Acid-Conjugated PLGA Ultrasmall Nanoparticle Loaded with Methotrexate as a Supercarrier for Bone-Targeted Drug Delivery.AAPS Pharm Sci Tech. 2017;18(6):2227-2239.
[17] HE Y, HUANG Y, HUANG Z, et al.Bisphosphonate-functionalized coordination polymer nanoparticles for the treatment of bone metastatic breast cancer.J Control Release.2017;264:76-88.
[18] YIN Q, TANG L, CAI K, et al.Pamidronate functionalized nanoconjugates for targeted therapy of focal skeletal malignant osteolysis.Proc Natl Acad Sci U S A.2016;113(32):E4601-4609.
[19] CHANG Q, GENG R, WANG S, et al.DOPA-based paclitaxel-loaded liposomes with modifications of transferrin and alendronate for bone and myeloma targeting.Drug Deliv.2016;23(9):3629-3638.
[20] SUN W, HAN Y, LI Z, et al.Bone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone Metastasis. Langmuir. 2016;32(36):9237-9244.
[21] SUN Y, YE X, CAI M, et al.Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery.ACS Nano. 2016;10(6): 5759-5768.
[22] WANG H, LIU J, TAO S, et al.Tetracycline-grafted PLGA nanoparticles as bone-targeting drug delivery system.Int J Nanomedicine. 2015;10: 5671-5685.
[23] FERREIRA DDOS S, BORATTO FA, CARDOSO VN, et al. Alendronate-coated long-circulating liposomes containing 99mtechnetium-ceftizoxime used to identify osteomyelitis.Int J Nanomedicine.2015;10:2441-2450.
[24] CONG Y, QUAN C, LIU M, et al.Alendronate-decorated biodegradable polymeric micelles for potential bone-targeted delivery of vancomycin. J Biomater Sci Polym Ed.2015;26(11):629-643.
[25] LIU J, DANG L, LI D, et al.A delivery system specifically approaching bone resorption surfaces to facilitate therapeutic modulation of microRNAs in osteoclasts.Biomaterials.2015;52:148-160.
[26] LIANG C, GUO B, WU H, et al.Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy.Nat Med.2015;21(3):288-294.
[27] JIANG T, YU X, CARBONE EJ, et al.Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.Int J Pharm.2014;475(1-2):547-557.
[28] SWAMI A, REAGAN MR, BASTO P, et al.Engineered nanomedicine for myeloma and bone microenvironment targeting.Proc Natl Acad Sci U S A. 2014;111(28):10287-10292.
[29] WANG F, CHEN L, ZHANG R, et al.RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.J Control Release.2014;196:222-233.
[30] CLARKE B.Normal bone anatomy and physiology.Am Soc Nephrol. 2008;3(Suppl 3):S131-139.
[31] CARBONE EJ, RAJPURA K, ALLEN BN,e t al.Osteotropic nanoscale drug delivery systems based on small molecule bone-targeting moieties. Nanomedicine.2017;13(1):37-47.
[32] RUSSELL RG.Bisphosphonates: The first 40 years.Bone. 2011;49(1): 2-19.
[33] BROWN JP, MORIN S, LESLIE W, et al.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays. Can Fam Physician.2014;60(4):324-333.
[34] FARRELL KB, KARPEISKY A,THAMM DH, et al.Bisphosphonate conjugation for bone specific drug targeting.Bone Rep.2018;9:47-60.
[35] COLE LE, VARGO-GOGOLA T, ROEDER RK.Targeted delivery to bone and mineral deposits using bisphosphonate ligands.Adv Drug Deliv Rev. 2016;99(Pt A):12-27.
[36] LAWSON MA, XIA Z, BARNETT BL, et al.Differences between bisphosphonates in binding affinities for hydroxyapatite.J Biomed Mater Res B Appl Biomater.2010;92(1):149-155.
[37] NANCOLLAS GH, TANG R, PHIPPS RJ, et al.Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone.2006;38(5):617-627.
[38] PULJULA E, TURHANEN P, VEPSALAINEN J, et al.Structural requirements for bisphosphonate binding on hydroxyapatite: NMR study of bisphosphonate partial esters.ACS Med Chem Lett. 2015;6(4):397-401.
[39] BROWN JP, MORIN S, LESLIE W, et al.Bisphosphonates for treatment of osteoporosis: expected benefits, potential harms, and drug holidays.Can Fam Physician.2014;60(4):324-333.
[40] CHOPRA I, ROBERTS M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev.2001;65(2):232-260.
[41] NEALE JR, RICHTER NB, MERTEN KE, et al.Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent.Bioorg Med Chem Lett.2009;19(3):680-683.
[42] CUTBIRTH ST.A Restorative Challenge: Tetracycline-Stained Teeth.Dent Today.2015;34(7):126,128-130.
[43] ISHIZAKI J, WAKI Y, TAKAHASHI-NISHIOKA T,et al.Selective drug delivery to bone using acidic oligopeptides.J Bone Miner Metab. 2009;27(1):1-8.
[44] JIANG T, YU X, CARBONE EJ, et al. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.Int J Pharm.2014;475(1-2):547-557.
[45] TAVAFOGHI M, CERRUTI M.The role of amino acids in hydroxyapatite mineralization.J R Soc Interface.2016;13(123).pii:20160462.
[46] TAKAHASHI T, YOKOGAWA K, SAKURA N, et al.Bone-targeting of quinolones conjugated with an acidic oligopeptide.Pharm Res. 2008;25(12):2881-2888.
[47] ZHANG Y, WEI L, MIRON RJ, et al. Anabolic bone formation via a site-specific bone-targeting delivery system by interfering with semaphorin 4D expression.J Bone Miner Res.2015;30(2):286-296.
[48] ZHANG G, GUO B, WU H, et al.A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy.Nat Med. 2012;18(2):307-314.
[49] WANG F, CHEN L, ZHANG R, et al.RGD peptide conjugated liposomal drug delivery system for enhance therapeutic efficacy in treating bone metastasis from prostate cancer.J Control Release.2014;196:222-233.
[50] ADDISON WN, MILLER SJ, RAMASWAMY J, et al. Phosphorylation-dependent mineral-type specificity for apatite-binding peptide sequences. Biomaterials.2010;31(36):9422-9430.
[51] DINJASKI N, PLOWRIGHT R, ZHOU S, et al.Osteoinductive recombinant silk fusion proteins for bone regeneration.Acta Biomater. 2017;49:127-139.
[52] ZHU G, CHEN X.Aptamer-based targeted therapy.Adv Drug Deliv Rev. 2018;134:65-78.
[53] CHENG H, CHAWLA A,YANG Y, et al. Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today. 2017;22(9):1336-1350.
[54] MIR M, AHMED N, REHMAN AU. Recent applications of PLGA based nanostructures in drug delivery. Colloids Surf B Biointerfaces. 2017; 159:217-231.
[55] PERES C, MATOS AI, CONNIOT J, et al. Poly(lactic acid)-based particulate systems are promising tools for immune modulation. Acta Biomater. 2017;48:41-57.
[56] XU Y, KIM CS, SAYLOR DM, et al.Polymer degradation and drug delivery in PLGA-based drug-polymer applications: A review of experiments and theories.J Biomed Mater Res B Appl Biomater.2017;105(6):1692-1716.
[57] MUSTAFA S, DEVI VK, PAI RS. Effect of PEG and water-soluble chitosan coating on moxifloxacin-loaded PLGA long-circulating nanoparticles. Drug Deliv Transl Res.2017;7(1):27-36.
[58] ZHANG K, TANG X, ZHANG J, et al.PEG-PLGA copolymers: their structure and structure-influenced drug delivery applications.J Control Release. 2014;183:77-86.
[59] CHEN X, CHEN J, LI B, et al.PLGA-PEG-PLGA triblock copolymeric micelles as oral drug delivery system: In vitro drug release and in vivo pharmacokinetics assessment.J Colloid Interface Sci.2017;490: 542-552.
[60] INZANA JA, SCHWARZ EM, KATES SL, et al.Biomaterials approaches to treating implant-associated osteomyelitis. Biomaterials. 2016;81:58-71.
[61] SEDGHIZADEH PP, SUN S, JUNKA AF, et al.Design, Synthesis, and Antimicrobial Evaluation of a Novel Bone-Targeting Bisphosphonate- Ciprofloxacin Conjugate for the Treatment of Osteomyelitis Biofilms. J Med Chem.2017;60(6):2326-2343.
[62] LI CJ, LIU XZ, ZHANG L, et al.Advances in Bone-targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for Osteosarcoma. Orthop Surg. 2016;8(2):105-110.
[63] DE LA PUENTE P, AZAB AK. Contemporary drug therapies for multiple myeloma.Drugs Today (Barc).2013;49(9):563-573.
[64] PATRIZI A, VENTURI M, DIKA E,e t al.Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.Cutan Ocul Toxicol.2014;33(1):1-6.
[65] ASAFO-ADJEI TA, CHEN AJ, NAJARZADEH A, et al.Advances in Controlled Drug Delivery for Treatment of Osteoporosis.Curr Osteoporos Rep. 2016;14(5):226-238.
[66] LI CJ, CHENG P, LIANG MK, et al.MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation.J Clin Invest. 2015;125(4):1509-1522.
|